KYORIN Holdings, Inc. Announces Consolidated Earnings Results for the Full Year Ended March 31, 2018; Provides Earnings for the First Half and Full Year of Fiscal Year Ending March 31, 2019
May 09, 2018
Share
KYORIN Holdings, Inc. announced consolidated earnings results for the full year ended March 31, 2018. For the year, the company reported net sales of JPY 110,640 million compared to JPY 115,373 million a year ago. Operating income was JPY 8,822 million compared to JPY 10,413 million a year ago. Ordinary income was JPY 9,345 million compared to JPY 10,874 million a year ago. Profit attributable to owners of parent was JPY 6,574 million or JPY 89.28 per share compared to JPY 7,305 million or JPY 99.45 per share a year ago. ROE was 4.1% compared to 4.6% a year ago. Cash flows from operating activities were JPY 10,456 million compared to JPY 16,386 million a year ago.
The company provided consolidated earnings guidance for the first half and full year of fiscal year ending March 31, 2019. For the first half, the company expects net sales of JPY 50,200 million, operating income of JPY 1,900 million, ordinary income of JPY 2,200 million and profit attributable to owners of parent of JPY 1,500 million or JPY 20.34 per share.
For the full year, the company expects net sales of JPY 114,400 million, operating income of JPY 8,600 million, ordinary income of JPY 9,200 million and profit attributable to owners of parent of JPY 6,600 million or JPY 89.49 per share.
Kyorin Pharmaceutical Co Ltd, formerly Kyorin Holdings Inc, is a Japan-based company mainly engaged in the pharmaceuticals business. The Pharmaceuticals segment is mainly engaged in the manufacture, purchase, sales and testing of pharmaceutical products, the purchase of raw materials for pharmaceuticals, the evaluation of technologies, the inspection, analysis and negotiation of license affiliations, the operations related to clinical trials and information gathering such as searching for drug discovery seeds, as well as the drug candidate compound discovery research and compound evaluation business. The Company also conducts the diagnostic businesses and verifies and creates research targets that are directly linked to drug discovery.
KYORIN Holdings, Inc. Announces Consolidated Earnings Results for the Full Year Ended March 31, 2018; Provides Earnings for the First Half and Full Year of Fiscal Year Ending March 31, 2019